Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease thrombocytopenia
Symptom C0019189|chronic hepatitis
Sentences 20
PubMedID- 24653754 In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy.
PubMedID- 21188328 The goal of this study is to determine the prevalent mechanism of thrombocytopenia in patients with chronic hepatitis c and the clinical predictors of its severity.
PubMedID- 25331767 Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c.
PubMedID- 25764686 thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment.
PubMedID- PMC4034027 Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity.
PubMedID- 20796208 Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review.
PubMedID- 22708981 Mechanism of thrombocytopenia in chronic hepatitis c as evaluated by the immature platelet fraction.
PubMedID- 19689996 thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation.
PubMedID- 25728497 Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc).
PubMedID- 24128106 Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports.
PubMedID- 20796207 Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye.
PubMedID- 24621321 We report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis c treated with pegylated interferon combined with ribavirin in spite of having the inosine triphosphatase-cc genotype.
PubMedID- 24304453 thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment.
PubMedID- 20720351 A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy.
PubMedID- 24731162 Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis.
PubMedID- 22327815 Causes of thrombocytopenia in chronic hepatitis c viral infection.
PubMedID- 22312391 However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis.
PubMedID- 23995112 Eltrombopag is effective for the treatment of chronic hepatitis with thrombocytopenia, and portal vein thrombosis at this time has rarely been reported.
PubMedID- 24714308 Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection .
PubMedID- 20731135 This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy.

Page: 1